Allergy Therapeutics' (LON:AGY) Nick Wykeman talks Proactive London through their preliminary full year results which include a 25% increase in pre-R&D operating profit to £14.2m (2019: £11.3m) as a result of sales growth and lower overhead cost growth.
Wykeman also talks through their strong cash position as they continue with their trials which include the Grass MATA MPL Phase III programme and the initial Phase I peanut trial - which he is confident are fully funded for.
